Publication Date
2018
Journal Title
Case Rep Gastroenterol
Abstract
© 2018 The Author(s). Published by S. Karger AG, Basel. Ixekizumab is a selective monoclonal antibody targeting interleukin-17A, approved for the treatment of chronic plaque psoriasis. It has rarely been associated with inflammatory bowel disease (IBD) in randomized trials only. We report a unique case of severe new-onset ulcerative colitis in a young male complicated by cytomegalovirus infection who was on ixekizumab therapy for plaque psoriasis. We recommend that clinicians should exercise caution before prescribing ixekizumab as it seems to induce and exacerbate IBD.
Volume Number
12
Issue Number
3
Pages
617-621
Document Type
Article
Status
Faculty
Facility
School of Medicine
Primary Department
Gastroenterology
PMID
DOI
10.1159/000493922